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Objective/background: May–Hegglin anomaly (MHA) is a rare familial bleeding disorder char-
acterized by a triad of thrombocytopenia, giant platelets, and Do¨hle-like inclusion bodies
within the leukocytes. The clinical spectrum as well as the pathophysiology of this entity is
not well defined. The objective of this work is to present a series of three cases of MHA diag-
nosed in our hospital, where the patients presented with variable bleeding manifestations,
thrombocytopenia, and giant platelets.
Materials and Methods: We studied three cases of possible MHA. In addition to the clinical
examination, complete hemogram, and peripheral blood smear examination, these patients
were also subjected to coagulation studies. Although bleeding symptoms varied among these
patients, platelet aggregation tests with various agonists showed a normal response.
Results: Consistent findings of this entity noted in our patients were mild-to-moderate throm-
bocytopenia, giant platelets, and Do¨hle-like inclusions within the leukocytes.
Conclusion: A diagnosis of MHA could be made based on a thorough peripheral blood smear
examination, which also helps to avoid a misdiagnosis of immune thrombocytopenia.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Platelet disorders are broadly classified as quantitative and
qualitative. Qualitative disorders of platelets are less
138 V. Kamath et al.frequent than the quantitative disorders. Thus, in clinical
practice, patients who present with bleeding diathesis and
low platelet counts are often misdiagnosed as having idio-
pathic thrombocytopenic purpura.
May–Hegglin anomaly (MHA) is a rare autosomal domi-
nant qualitative platelet disorder. The bleeding symptoms
vary from mild-to-moderate severity among individuals
depending on the degree of thrombocytopenia. Most
patients are asymptomatic and do not require medical inter-
vention. However, low platelet count comes to attention
when individuals present with bleeds following minor proce-
dures, although fatal bleeding diathesis have also been
reported occasionally [1,2].
Thus, misdiagnosis of this entity as thrombocytopenic
purpura has resulted in low incidence of this condition. This
also leads to incorporation of erroneous treatment proto-
cols including administration of immunosuppressive agents
and in some cases splenectomy.
Here, we present a series of three cases of MHA diag-
nosed in our hospital, where the patients presented with
variable bleeding manifestations, thrombocytopenia, and
giant platelets.Materials and methods
A retrospective study was conducted in the Department of
Transfusion medicine and Immunohematology for a 5-year
period between 2010 and 2014. Patients whose Wright–
Giemsa-stained blood smear showed Do¨hle-like inclusions
were subjected to complete coagulation workup, which
included evaluation of complete blood counts (CBC – SYS-
MEX XN9000, Japan), bleeding time, prothrombin time
(PT), activated partial thromboplastin time (aPTT), and
thrombin time (TT) using an automated coagulation ana-
lyzer (SYSMEX CS2000i, Japan). Platelet function study with
light transmission aggregation was performed in the platelet
aggregometer (CHRONOLOG 560VF, USA) with a set of five
agonists: ristocetin (0.5 mg/mL and 1.5 mg/mL), adenosine
diphosphate (10 lmol/mL), collagen (2 lmol/mL), arachi-
donic acid (10 lmol/mL), and epinephrine (10 lmol/mL).
Controls were run in parallel with the experimental
samples.Fig. 1 Peripheral blood film (Wright–Giemsa stain). Do¨hle-
like inclusions in the cytoplasm of neutrophils (long arrow) and
giant platelets (short arrow). Magnification: 400.Case 1
A 22-year-old woman presented to the Department of
Hematology (Christian Medical College, Vellore) with a his-
tory of prolonged mucocutaneous bleeds following trivial
injuries. There was no history of decreased urinary output,
and her CBC revealed the following measurements: hemo-
globin (Hb), 132 g/L; total white cell count (TC),
8.3  109/L; and automated platelet count, 30  109/L.
On the peripheral blood examination, platelet count ranged
between 75,000/mm3 and 90,000/mm3 with predominance
of giant platelets. Importantly, we observed solitary,
spindle-shaped, pale sky blue-colored inclusion body local-
ized within the cytoplasm of neutrophils and monocytes.
A complete coagulation workup was done. Bleeding time,
PT, aPTT, and TT were all within normal limits. Platelet
function studies with light transmission aggregation showeda normal response. Based on the presence of Do¨hle-like
inclusions within the cytoplasm of the leukocytes and
macrothrombocytopenia, a diagnosis of possible MHA was
made (Fig. 1).
Case 2
A 20-year-old man presented with recent onset of epistaxis.
He was diagnosed with juvenile nasopharyngeal angiofi-
broma and underwent excision, requiring transfusion. His
CBC profile revealed the following measurements: Hb,
113 g/L; TC, 17.4  109/L; and platelet count, 38  109/L
on automated cell analyzer and 85,000/mm3 on smear.
Peripheral smear showed characteristic spindle-shaped,
pale blue inclusions within the cytoplasm of neutrophils
and monocytes, in addition to the giant platelets and neu-
trophilia (Fig. 2A and B). His bleeding time was mildly pro-
longed (7 min), although results of aggregation studies
were within normal limits. In addition, PT, aPTT, and TT
were normal.
Case 3
A 25-year-old man, born out of nonconsanguineous mar-
riage, was found to have low platelet count during routine
preoperative workup and was referred for coagulation stud-
ies. There was no history of bleeding tendency and visual or
hearing difficulties. However, he had a family history of
bleeding from the maternal side. CBC tests showed the
following measurements: Hb, 152 g/L; TC, 5.6  109/L;
platelet count, 14  109/L on automated analyzer and
15,000–30,000/mm3 on smear with giant platelets. On
smear, the characteristic spindle-shaped inclusions were
seen within the neutrophilic cytoplasm. PT, aPTT, and TT
were all normal and aggregation study was inconclusive
due to the low platelet count. His mother’s blood film
showed similar findings. This also stands as a supportive evi-
dence towards the diagnosis of MHA, as it follows autosomal
dominant inheritance.
Fig. 2 (A and B) Peripheral blood film (Wright–Giemsa stain).
The long arrow shows giant platelets and the short arrow points
to the spindle-shaped Do¨hle-like inclusion (magnification: 100
and 400).
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In this case series, there were two male patients and one
female patient (M:F = 2:1), and their age group was
between 20 years and 25 years. All the three patients
showed Do¨hle-like inclusions in the peripheral blood. Bleed-
ing manifestation was seen in two patients (n = 2/3), of
which one case showed a mildly prolonged bleeding time
(n = 1/3). PT, aPTT, and TT were within normal limits in
all the three cases (n = 3/3). Furthermore, platelet aggrega-
tion studies were well within normal range (n = 3/3). CBC
profile showed a platelet count less than 100,000/mm3 inTable 1 Complete blood profile.
Case Age Sex Hemoglobin (g/L) Total count (
1 20 Male 113 17.4
2 22 Female 132 8.3
3 25 Male 152 5.6all the three cases, and levels of Hb ranged between 11 g/
dL and 15.5 g/dL (Table 1).
MHA is an autosomal dominant condition characterized
by a triad of thrombocytopenia; giant platelets; and bluish,
spindle-shaped, well-delineated cytoplasmic inclusions
(resembling Do¨hle bodies) within the leukocytes. This condi-
tion was first described in 1909 by Richard May, a German
physician, and later in 1945 by Hegglin, a Swiss physician
[3].
This entity is described under MYH9-related disorders
(MYH9RDs). These disorders are due to a defect in the
MYH9 gene, which encodes nonmuscle myosin heavy-chain
Class IIA [4,5]. Other disorders included in this entity are
Sebastian syndrome, Fechtner syndrome, and Epstein syn-
drome [6,7].
In 1909, the presence of large platelets and sky blue
inclusions localized within the cytoplasm of neutrophils,
eosinophils, and monocytes were described [4,8]. Subse-
quently, macrothrombocytopenia along with Do¨hle-like
inclusions in the leukocytes was noted among several symp-
tomatic members of a single family and this condition was
named as MHA [4].
So far, the pathogenesis of MHA is not clearly under-
stood, although thrombocytopenia was considered as the
cause of bleeding [8]. However, it has been observed that
in patients with near-normal platelet counts, bleeding ten-
dency is attributed to dysfunctional platelets. Dysfunctional
platelets are thought to be due to a defect in the platelet
tubulin. The tubulins are unevenly distributed instead of
the normal circumferential pattern, resulting in abnormal
structure and defective function [9].
The defective tubulin and the large-sized platelets are
probably responsible for reduced clot stability. Therefore,
itwas proposed that the severity of bleeding is the summative
effect of low platelet count and a qualitative defect [8,9].
Ultrastructurally, the inclusions within the cytoplasmic
periphery of polymorphonuclear leukocytes are oval or
round granules, ribosomal filaments of amorphous densities,
and do not contain specific granules [10]. They are com-
posed of ribonucleic acid and are devoid of a limiting mem-
brane, and mainly contain deposits of defective nonmuscle
myosin heavy-chain protein [9].
Immunofluorescence is a highly sensitive method to
detect the abnormal protein aggregates [11]. However, con-
firmatory diagnosis is made by molecular testing for the
MYH9 gene [12]. The most common mutations occur in the
motor region of nonmuscle myosin heavy-chain Class IIA
and these have a higher risk of developing systemic compli-
cations when compared with mutations of the tail region
[13–15]. Therefore, a mutational study is required not only
for confirmation, but also to identify those patients at risk




140 V. Kamath et al.Other MYH9RDs include Fechtner syndrome, Sebastian
syndrome, and Epstein syndrome, which are characterized
by defective nonmuscle myosin heavy-chain protein and
congenital macrothrombocytopenia. These syndromes rep-
resent a continuous clinical spectrum of a single disease
with findings ranging from mild macrothrombocytopenia
with leukocyte inclusions to a more systemic illness compli-
cated by hearing, visual loss and renal failure. Therefore,
MYH9RD is proposed as a new term to redefine this group
of disorders and thereby identify all patients at risk of
developing systemic complications [16]. Although
macrothrombocytopenia is a common finding in all four syn-
dromes, the presence of a large, solitary, spindle-shaped
inclusion is a pathognomonic feature seen only in MHA.
However, the clinical features can evolve over time and
the appearance of new symptoms can lead to reclassifica-
tion of the MYH9RD spectrum [14].
Patients with bleeding diathesis and thrombocytopenia
are often misdiagnosed as having immune thrombocytope-
nia if the Do¨hle-like inclusion bodies are not correctly iden-
tified in the peripheral smear. The rarer conditions, which
mimic MHA, are Von Willebrand disease Type 2b,
Bernard–Soulier syndrome, Paris–Trousseau/Jacobson syn-
drome, Grey platelet syndrome, and X-linked recessive
macrothrombocytopenia.
Bernard–Soulier syndrome and Von Willebrand disease
Type 2b are familial bleeding disorders and macrothrombo-
cytopenia is a common finding in the former. Both of these
conditions invariably present with an abnormal coagulation
profile. Paris–Trousseau/Jacobson syndrome is a disorder
with large platelets consisting of abnormal alpha granules
and micromegakaryocytes in the marrow along with mental
retardation, facial and cardiac anomalies [17]. There is
another X-linked recessive disorder presenting with
macrothrombocytopenia and mild dyserythropoiesis, caused
by mutation in GATA1 gene [18]. However, none of these
conditions has Do¨hle-like inclusions as described in MHA.
Accurate diagnosis of platelet disorders is required for
prompt management of bleeding. MYH9RD involves defec-
tive platelets in addition to thrombocytopenia, hence all
medications that hamper the function of platelets should
be avoided. Treatment is mainly supportive; steroids,
immunosuppressive agents, and splenectomy are not
effective. Mild-to-moderate bleeders are managed with
desmopressin support, whereas severe bleeders require
platelet-rich concentrates [19]. Recently, a thrombopoietin
receptor agonist, eltrombopag, has been proven to be
effective in these patients [11,19].Conclusion
MYH9RD is often underreported and frequently misdiag-
nosed as immune thrombocytopenia. A careful assessment
of the peripheral blood film is important and the triad of
thrombocytopenia, giant platelets, and Do¨hle-like inclu-
sions could help in the correct diagnosis of this condition.
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